Skip to content

Newsroom

type
year
Illustration image.png

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

8/8/2025 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Satu Ahomäki

8/4/2025 Managers transactions
orionpharma_wehale2_paakuva_1500x844.jpg

Living well with asthma: How Nordic practices empower patients

8/4/2025 Your Health
Illustration image.png

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

7/21/2025 Press release
Illustration image.png

Orion Group Half-Year Financial Report January–June 2025

7/18/2025 Stock exchange release
Illustration image.png

Orion Corporation’s financial reporting and Annual General Meeting in 2026

7/18/2025 Stock exchange release
orionpharma_pettalk_paakuva_1500x844.jpg

Understanding your dog and cat: 7 common mistakes pet owners make — and how to avoid them

7/17/2025 Your Health
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2025

7/9/2025 Stock exchange release
Illustration image.png

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025

7/4/2025 Press release
orionpharmacom_laaketurvallisuus_paakuva_1500x844.jpg

Medicine safety is monitored throughout its entire lifecycle

7/4/2025 Sustainability
Illustration image.png

141,959 Orion Corporation A shares converted into B shares

6/23/2025 Stock exchange release
Illustration image.png

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

6/20/2025 Press release
Illustration image.png

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

6/17/2025 Press release
orionpharmacom_marketinghealthcare_1500x844.jpg

Patients benefit most from seamless cooperation between pharmaceutical companies and healthcare

6/13/2025 Orion and Society
Illustration image.png

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

6/3/2025 Press release
Illustration image.png

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

5/23/2025 Press release
Illustration image.png

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

5/22/2025 Press release
Illustration image.png

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers

5/21/2025 Press release